Aspirin and breast cancer risk
This article was originally published in The Tan Sheet
The use of aspirin and other non-steroidal anti-inflammatory drugs and acetaminophen is not associated with a reduced risk of breast cancer among premenopausal women in a study published online in the Internal Archives of Medicine Jan. 26. Led by Harvard researcher A. Heather Eliassen, the trial followed 112,292 women ages 25 to 42 who completed a lifestyle questionnaire for the Nurses' Health Study II in 1989; subjects were followed through 2003. Overall, 1,345 cases of invasive premenopausal breast cancer were documented. Results did not vary by frequency, dose or duration of use. The findings run counter to a meta-analysis published in the Oct. 7 Journal of National Cancer Institute, which concluded NSAIDs, including aspirin and ibuprofen, are associated with a reduced risk of breast cancer (1"The Tan Sheet" Oct. 13, 2008, In Brief)
You may also be interested in...
Non-steroidal anti-inflammatory drug use, including aspirin and ibuprofen, is associated with a reduced risk of breast cancer, according to a meta-analysis published Oct. 7 in the Journal of National Cancer Institute. The review of 38 studies conducted between January 1966 and July 2008 found women using NSAIDs were 12 percent less likely to develop breast cancer than women who did not. Ibuprofen use reduced the risk by 21 percent and aspirin use by 13 percent. The study did not find that higher doses or longer duration - especially of aspirin or ibuprofen - further reduced the risk of breast cancer. Researchers, led by Bahi Takkouche at the University of Santiago de Compostela in Spain, acknowledge weaknesses in the meta-analysis, including not considering other drugs participants took
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.